Document Type : Mini-Review
Department of Biology, Faculty of Science, Khorramabad, Lorestan University, Lorestan, Iran
Department of Biological Science, Faculty of Science, University of Kurdistan, Sanandaj, Kurdistan, Iran
Vincristine and its derivatives as an alkaloid have been applied in combination with chemotherapeutic drugs for the inhibition of several cancers involving small-cell lung cancer, lymphocytic leukemia, Hodgkin's disease, acute myeloid leukemia, and neuroblastoma. The main advantage of using this bioactive compound is its severe side effects specifically dose-dependent peripheral neuropathy (brain dysfunction, cranial nerve palsies, paresthesia, and gait disorder). Combination therapy using other anticancer drugs or anticancer natural compounds can synergize anticancer effects. Moreover, drug delivery systems in the nanoscale may be suitable options to decrease side effects by reducing an effective dose of vincristine. Therefore, this mini-review has tried to cover recent progress and limitations of vincristine formulations for cancers of lung cancer, acute lymphocytic leukemia, and acute myeloid leukemia.